Predominance of a Proinflammatory Phenotype in Monocyte-Derived Macrophages From Subjects With Low Plasma HDL-Cholesterol

Objective—Reduced plasma concentrations of high-density lipoprotein-cholesterol (HDL-C) are a significant risk factor for cardiovascular disease. Mechanisms that regulate HDL-C concentrations represent an important area of investigation. Methods and Results—Comparative transcriptome analyses of monocyte-derived macrophages (MDM) from a large population of low HDL-C subjects and age- and sex-matched controls revealed a cluster of inflammatory genes highly expressed in low HDL-C subjects. The expression levels of peroxisome proliferator activated receptor (PPAR) γ and several antioxidant metallothionein genes were decreased in MDM from all low HDL-C groups compared with controls, as was the expression of other genes regulated by PPARγ, including CD36, adipocyte fatty acid binding protein (FABP4), and adipophilin (ADFP). In contrast, PPARδ expression was increased in MDM from low HDL-C groups. Quantitative RT-PCR corroborated all major findings from the microarray analysis in two separate patient cohorts. Expression of several inflammatory cytokine genes including interleukin 1β, interleukin 8, and tumor necrosis factor α were highly increased in low HDL-C subjects. Conclusions—The activated proinflammatory state of monocytes and MDM in low HDL-C subjects constitutes a novel parameter of risk associated with HDL deficiency, related to altered expression of metallothionein genes and the reciprocal regulation of PPARγ and PPARδ.

[1]  M. Freeman,et al.  Genetic Etiology of Isolated Low HDL Syndrome: Incidence and Heterogeneity of Efflux Defects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. Hayden,et al.  Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. , 2006, Annual review of nutrition.

[3]  Peter Tontonoz,et al.  The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis. , 2006, Molecular endocrinology.

[4]  Hongyue Dai,et al.  Rosetta error model for gene expression analysis , 2006, Bioinform..

[5]  J. Heinecke.  Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander? , 2006, The Journal of experimental medicine.

[6]  R. Evans,et al.  PPARδ: a dagger in the heart of the metabolic syndrome , 2006 .

[7]  Amir Gamliel,et al.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ , 2005, Nature.

[8]  R. Blumenthal,et al.  Low HDL Cholesterol Levels , 2005 .

[9]  G. Anantharamaiah,et al.  The role of high-density lipoprotein in inflammation. , 2005, Trends in cardiovascular medicine.

[10]  T. Wurch,et al.  Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor γ Ligands , 2004, Journal of Pharmacology and Experimental Therapeutics.

[11]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[12]  B. Brewer,et al.  Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[13]  L. Makowski,et al.  Fatty acid binding proteins--the evolutionary crossroads of inflammatory and metabolic responses. , 2004, The Journal of nutrition.

[14]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[15]  F. Spener,et al.  Fatty acid-binding proteins--insights from genetic manipulations. , 2004, Progress in lipid research.

[16]  William A. Boisvert,et al.  Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.

[17]  M. Hayden,et al.  Efflux and Atherosclerosis: The Clinical and Biochemical Impact of Variations in the ABCA1 Gene , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[18]  R. S. Kiss,et al.  Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations , 2003, Current opinion in lipidology.

[19]  W. Wahli,et al.  Peroxisome proliferator-activated receptors β/δ: emerging roles for a previously neglected third family member , 2003 .

[20]  Peng Liu,et al.  Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription , 2002, Molecular and Cellular Biology.

[21]  A. Gotto,et al.  Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. , 2002, The Journal of biological chemistry.

[22]  Michael J. Thomas,et al.  The effects of altered apolipoprotein A-I structure on plasma HDL concentration. , 2002, Trends in cardiovascular medicine.

[23]  H. Vosper,et al.  The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages* , 2001, The Journal of Biological Chemistry.

[24]  J. Hidalgo,et al.  Metallothionein Treatment Reduces Proinflammatory Cytokines IL-6 and TNF-α and Apoptotic Cell Death during Experimental Autoimmune Encephalomyelitis (EAE) , 2001, Experimental Neurology.

[25]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[26]  M. Aschner,et al.  Roles of the metallothionein family of proteins in the central nervous system , 2001, Brain Research Bulletin.

[27]  J. Brady,et al.  Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice* , 2001, The Journal of Biological Chemistry.

[28]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Reddy,et al.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.

[30]  J. Auwerx,et al.  Activation of PPARδ alters lipid metabolism in db/db mice , 2000 .

[31]  I. Yuhanna,et al.  High Density Lipoprotein Prevents Oxidized Low Density Lipoprotein-induced Inhibition of Endothelial Nitric-oxide Synthase Localization and Activation in Caveolae* , 2000, The Journal of Biological Chemistry.

[32]  A. Tall,et al.  Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. , 2000, Journal of lipid research.

[33]  B. Spiegelman,et al.  Regulation of Peroxisome Proliferator-Activated Receptor γ Expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: Implications for Adipocyte Differentiation and Metabolism , 1999, Molecular and Cellular Biology.

[34]  A. Tall,et al.  Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.

[35]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[36]  G. Luc,et al.  Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. , 1997, Metabolism: clinical and experimental.

[37]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[38]  Richard H. Myers,et al.  Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.

[39]  S. De,et al.  Endotoxin induction of murine metallothionein gene expression. , 1990, The Journal of biological chemistry.

[40]  R. Cousins,et al.  Interleukin 6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.

[42]  R. Evans,et al.  PPAR delta: a dagger in the heart of the metabolic syndrome. , 2006, The Journal of clinical investigation.

[43]  R. Blumenthal,et al.  Clinical practice. Low HDL cholesterol levels. , 2005, The New England journal of medicine.

[44]  W. Wahli,et al.  Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member. , 2003, Current opinion in lipidology.

[45]  D. Altshuler,et al.  The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. , 2001, Nature medicine.

[46]  R. Evans,et al.  A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. , 2001, Molecular cell.

[47]  D. Altshuler,et al.  The role of PPAR-γ in macrophage differentiation and cholesterol uptake , 2001, Nature Medicine.

[48]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[49]  G. Fonarow,et al.  formation of , 2022 .

[50]  J. Auwerx,et al.  Activation of PPARdelta alters lipid metabolism in db/db mice. , 2000, FEBS letters.

[51]  M. Brown,et al.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Eng,et al.  Genetic Variation in PLTP Modulates Lipoprotein Profiles in Hyperalphalipoproteinemia , 2022 .